-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $31

Benzinga·02/03/2026 12:29:57
Listen to the news
Leerink Partners initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $31.